SARS-CoV-2
24 competing products in clinical development for SARS-CoV-2.
Pipeline by Phase
Phase 11
Phase 23
Phase 39
Approved2
Preclinical9
All Products (24)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| S-268019-b + Placebo | Shionogi | Phase 3 | Completed | 40 |
| mRNA-1273 | Moderna | Preclinical | Completed | 0 |
| mRNA-1283 | Moderna | Phase 1 | Completed | 0 |
| mRNA-1273 | Moderna | Preclinical | Terminated | 0 |
| mRNA-1273.214 | Moderna | Phase 2 | Terminated | 0 |
| SPIKEVAX | Moderna | Preclinical | Completed | 0 |
| mRNA-1273 | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273 | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273 | Moderna | Preclinical | Completed | 0 |
| SPIKEVAX Bivalent | Moderna | Preclinical | Recruiting | 0 |
| mRNA-1273 | Moderna | Phase 2 | Completed | 0 |
| mRNA-1273 | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273 | Moderna | Preclinical | Completed | 0 |
| mRNA-1273.211 | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273 | Moderna | Preclinical | Completed | 0 |
| mRNA-1283 | Moderna | Phase 2 | Completed | 0 |
| mRNA-1273 | Moderna | Phase 3 | Completed | 0 |
| A Study to Determine Antibody Levels After Receiving COVID-19 Boosters of Any Ki | Moderna | Preclinical | Completed | 0 |
| mRNA-1273 Variant-containing Formulation | Moderna | Approved | Recruiting | 0 |
| Licensed Spikevax Vaccine | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273.529 | Moderna | Phase 3 | Completed | 0 |
| mRNA-1273 | Moderna | Preclinical | Completed | 0 |
| mRNA-1273 | Moderna | Approved | Recruiting | 0 |
| mRNA-1273.214 | Moderna | Phase 3 | Completed | 0 |